Aptahem AB (publ) (NGM:APTA)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.190
0.00 (0.00%)
At close: Jun 27, 2025
-59.80%
Market Cap 19.77M
Revenue (ttm) 3.33M
Net Income (ttm) -7.85M
Shares Out 17.26M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38,552
Average Volume 28,734
Open 1.210
Previous Close 1.190
Day's Range 1.190 - 1.240
52-Week Range 0.560 - 4.500
Beta 0.41
RSI 52.35
Earnings Date Aug 28, 2025

About Aptahem AB

Aptahem AB (publ), a biotechnology company, develops and sells aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. The company’s lead products candidate is Apta-1, which is in preclinical stage to prevent the onset of life-threatening organ and tissue damage in sepsis patients. It has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Swed... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol APTA
Full Company Profile

Financial Performance

In 2024, Aptahem AB's revenue was 3.77 million, a decrease of -63.95% compared to the previous year's 10.46 million. Losses were -8.57 million, -22.90% less than in 2023.

Financial Statements

News

There is no news available yet.